stableBearishPHARMACEUTICALS
Servier's muscular dystrophy drug fails late-stage trial after $1.55B acquisition
3 signals from 2 sources·Updated Yesterday
Momentum
40/100
Summary
Servier's sevasemten, acquired from Edgewise Therapeutics for $1.55 billion, failed to meet efficacy goals in its pivotal Phase III trial for Becker muscular dystrophy despite earlier Phase II success. The failure wipes…
Impact
Contributing sources (3)
- Servier Phase III trial for $1.55 billion muscular dystrophy drug fails to meet goals · clinicaltrialsarena.com · 4 days ago
- Servier's $1.55bn muscular dystrophy drug fails Phase II BMD trial · clinicaltrialsarena.com · 4 days ago
- Servier's sevasemten fails pivotal test in Becker muscular dystrophy · medcitynews.com · 3 days ago
Get the full Trend Briefing
Impact. Contributing sources. Momentum and affected tickers. Every emerging narrative gets a structured briefing on Whisper Media.
Create your free accountTrend Briefings available on Pro ($69/mo)
Trend Briefings are AI-generated from public sources. They are not financial advice and do not predict outcomes. Always do your own research before making investment decisions.